Brought to you by 
ElsaLys Biotech spins out of Transgene, raises €2.1mm in Series A round
31 May 2013
Executive Summary
Immunotherapeutics company Transgene SA (majority owned by Institut Merieux) has spun out ElsaLys Biotech, and participated in the monoclonal antibody firm’s €2.1mm ($2.7mm) Series A round, which also included Sofimac Partners.
Deal Industry
- Pharmaceuticals
-
Biotechnology
-
Large Molecule
- Antibodies
-
Large Molecule
Deal Status
- Final
Deal Type
-
Financing
- Private Placement
- Spin-Off
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com